Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.93 |
| ▸ | PGR | P06401 | 5/20 | 0.93 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.93 |
| ▸ | MAPT | P10636 | 2/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.93 |
| ▸ | DRD2 | P14416 | 1/20 | 0.93 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.78 |
| ▸ | USP2 | O75604 | 5/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | MLNR | O43193 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.78 |
| ▸ | PPARG | P37231 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.75 |
| ▸ | CNR1 | P21554 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Dipropionate SCHEMBL1658520 | 0.97 | NR3C1 (0.88) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL13028946 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL11429865 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL7519 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL10013893 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL9768468 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL20097870 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Dexamethasone Dipropionate SCHEMBL43107 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL4566 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL14339597 | 0.96 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-4399208-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | Rigel Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4393547-A2 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-110290807-B | Methods of determining CAR-T cell dosing | 朱诺治疗学股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240165160-A1 | EFFICACY AND DURABLE RESPONSE OF IMMUNOTHERAPY | KITE PHARMA, INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024097905-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240151713-A1 | ARTICLES OF MANUFACTURE AND METHODS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240151713-A1 | ARTICLES OF MANUFACTURE AND METHODS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | TNF, IL2, PBK | NR3C1 905/4885PGR 1498/4885NR1I2 4496/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | NR3C1 413/4885PGR 2470/4885NR1I2 3416/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | NR3C1 132/4885PGR 1869/4885NR1I2 84/4885 |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | NR3C1 31/4885PGR 763/4885NR1I2 1040/4885 |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | NR3C1 31/4885PGR 763/4885NR1I2 1040/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | NR3C1 413/4885PGR 2470/4885NR1I2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.